Recent News

• 06.11.2025 - Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
• 06.10.2025 - Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
• 06.09.2025 - Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
• 05.29.2025 - Axsome Therapeutics to Participate in Upcoming Investor Conferences
• 05.28.2025 - Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

Recent Filings

• 06.10.2025 - 8-K Current report
• 06.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2025 - EX-99.1 EX-99.1
• 06.09.2025 - 8-K Current report
• 06.09.2025 - 144 Report of proposed sale of securities
• 06.09.2025 - 8-K Current report